Prevalence of inhibitors and clinical characteristics in patients with haemophilia in a middle-income Latin American country.
Laura Villarreal MartinezJaime García-ChávezBerenice Sánchez-JaraAida Mashenka Moreno-GonzálezJanet Soto-PadillaEfraín Aquino-FernándezRogelio Paredes-AguileraKarla Maldonado-SilvaCecilia Rodríguez-CastillejosAna Itamar González-ÁvilaMaría Mora-TorresHector Manuel Tiznado-GarcíaNatalia Elizabeth Padilla-DurónNuria Citlali Luna-SilvaEric Israel Gutiérrez-JuárezJorge Nemi-CuetoClaudia Sofia Gómez-GonzálezRicardo De León-FigueroaAdela López-MirandaMirna Guadalupe Ríos-OsunaEdna Liliana Tamez-GómezElio Aarón Reyes-EspinozaIrving Armando Domínguez-VarelaGerardo Gonzalez-MartinezElias Adán Godoy-SalinasPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)
In Mexico, the general prevalence of inhibitors varies considerably among centres. This study established a basis of comparison for future development and advances in the treatment and follow-up of patients. These findings also augment our understanding of risk factors related to inhibitor development.